While PD-L1–overexpressing tumours tend to have more intense responses, experience with melanoma suggests that PD-1/PD-L1 blockade may be beneficial also in patients with low PD-L1 expression (11–13), therefore a negative PD-L1 status assessment should not definitively preclude the use of ICIs. The gene discussed is PDCD1; the disease is neoplasm.